HC Wainwright & Co. analyst Mitchell Kapoor maintains Lyell Immunopharma (NASDAQ:LYEL) with a Buy and lowers the price target from $11 to $9.
Schwazze Q1 FY23 Revenue Grows 26% YoY, What About Profit?
Medicine Man Technologies Inc. operating as Schwazze, (OTCQX: SHWZ) (NEO:SHWZ) released financial results for the first quarter 2023, revealing revenue of $40 million, an increase of 26% compared to $31.8 million in Q1 2022.
